Drug intelligence / Profile preview

DayZero

Development stage: Unknown
Lead developer: ZEO ScientifiX
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intraarticular, Local Injection

Overview

DayZero is an allogeneic stem cell therapy developed by ZEO ScientifiX, derived from human umbilical cord tissue, specifically Wharton's Jelly. As a mesenchymal stem cell (MSC) biologic, it is designed for use in regenerative medicine to treat orthopedic injuries, inflammatory conditions, and degenerative diseases. The product is processed to maintain high cell viability and a rich profile of regenerative factors, including cytokines and growth factors. In early 2026, ZEO ScientifiX established a manufacturing partnership with Cytora Therapeutics and Made Scientific to scale the production of DayZero and other allogeneic therapies within the United States.

Brand names: DayZero
Other names: DayZero stem cells

Beyond the preview

Go deeper on DayZero.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DayZero.

Explore the full profile